Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 101 - 110 of 152

Selected Filters:
7 July 2022

InsidemyPurse.co.za

Inside My Purse is a blog which aims to create a supportive and informative space where adolescent girls and young women in sub-Saharan Africa can share and engage with content about sexual and reproductive health and rights, including HIV/AIDS and gender-based violence.

Community/Advocacy

External Link
7 July 2022

MTN-023/IPM 030 “iMatter”

Microbicide Trials Network-023/International Partnership for Microbicides 030 was a Phase 2a trial to assess safety of the dapivirine vaginal ring in HIV-uninfected adolescent females

Research, Service Delivery

External Link
7 July 2022

A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical

In this episode of Px Pulse, the Dapivirine Vaginal Ring is center stage. After decades of research and advocacy, the ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in…

Community/Advocacy

External Link
7 July 2022

After The Ring Study: DREAM

DREAM, or Dapivirine Ring Extended Access and Monitoring, was a year long open-label extension (OLE) study launched by the International Partnership for Microbicides (IPM) in 2019 to assess how safe the ring is for the 940 HIV- women who participated in The Ring Study, and explores when, why, and how women use the ring.

Community/Advocacy

External Link
7 July 2022

Safety, Adherence and HIV-1 Seroconversion in DREAM – An Open-label Dapivirine Vaginal Ring Trial

The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article features a report on the DREAM study, which aimed to evaluate safety, adherence,…

Research

Document
7 July 2022

Final Results of Open-label Study of IPM’s Dapivirine Vaginal Ring Show Increased Use and Suggest Lower Infection Rates Compared to Earlier Phase III Study

This letter from the International Partnership for Microbicides outlines the results of an open-label study on the Dapivirine Vaginal Ring

Research

External Link
7 July 2022

Results of open-label study of a vaginal ring for HIV prevention suggest women are interested in and willing to use it

This article from the Microbicide Trials Network shares the results of an open-label study of a vaginal ring for HIV prevention

Community/Advocacy, Demand Creation/Marketing, Research

External Link
7 July 2022

Adherence to the Dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study

Adolescent girls and young women (AGYW) account for most new HIV infections in sub-Saharan Africa. WHO has endorsed oral PrEP and dapivirine vaginal ring (ring) for women at substantial risk of HIV infection. However, adherence to both products was lower among younger women in randomized placebo-controlled trials. The authors of this article assessed interim safety,…

Research

External Link
7 July 2022

Microbicide Trials Network-042 – DELIVER Study

Microbicide Trials Network-042/DELIVER is a Phase IIIb open-label study designed to evaluate the safety and acceptability of the monthly dapivirine vaginal ring and oral PrEP in pregnant women.

Research

External Link
7 July 2022

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Community/Advocacy

External Link